Mohammed M, Kulasekara K, Ootsuka Y, Blessing WW. Locus coeruleus noradrenergic innervation of the amygdala facilitates alerting-induced constriction of the rat tail artery. Am J Physiol Regul Integr Comp Physiol 310: R1109 -R1119, 2016. First published April 13, 2016 doi:10.1152/ajpregu.00058.2016.-The amygdala, innervated by the noradrenergic locus coeruleus, processes salient environmental events. ␣2-adrenoceptor-stimulating drugs (clonidine-like agents) suppress the behavioral and physiological components of the response to salient events. Activation of sympathetic outflow to the cutaneous vascular bed is part of the physiological response to salience-mediated activation of the amygdala. We have determined whether acute systemic and intra-amygdala administration of clonidine, and chronic immunotoxin-mediated destruction of the noradrenergic innervation of the amygdala, impairs salience-related vasoconstrictor episodes in the tail artery of conscious freely moving SpragueDawley rats. After acute intraperitoneal injection of clonidine (10, 50, and 100 g/kg), there was a dose-related decrease in the reduction in tail blood flow elicited by alerting stimuli, an effect prevented by prior administration of the ␣ 2-adrenergic blocking drug idazoxan (1 mg/kg ip or 75 nmol bilateral intra-amygdala). A dose-related decrease in alerting-induced tail artery vasoconstriction was also observed after bilateral intra-amygdala injection of clonidine (5, 10, and 20 nmol in 200 nl), an effect substantially prevented by prior bilateral intraamygdala injection of idazoxan. Intra-amygdala injection of idazoxan by itself did not alter tail artery vasoconstriction elicited by alerting stimuli. Intra-amygdala injection of saporin coupled to antibodies to dopamine-␤-hydroxylase (immunotoxin) destroyed the noradrenergic innervation of the amygdala and the parent noradrenergic neurons in the locus coeruleus. The reduction in tail blood flow elicited by standardized alerting stimuli was substantially reduced in immunotoxin-treated rats. Thus, inhibiting the release of noradrenaline within the amygdala reduces activation of the sympathetic outflow to the vascular beds elicited by salient events.
the locus coeruleus (23, 46) . Consistent with this anatomical arrangement, evidence from diverse experimental models suggests that the locus coeruleus contributes substantially to the processing of salient events (2) (3) (4) (5) (6) (7) (8) . The adrenergic receptors associated with the noradrenaline-synthesizing input to the amygdala include the ␣ 2 subtype, located principally presynaptically on the noradrenaline-synthesizing nerve terminals (37, 57, 59, 63, 64, 66, 67, 75) . Activation of these ␣ 2 -adrenoceptors inhibits release of noradrenaline (26, 36, 50, 68) .
When ambient temperature is within the thermoneutral range, salient stimuli powerfully activate the brain centers controlling sympathetic outflow to the thermoregulatory cutaneous vascular beds, resulting in sudden intense vasoconstriction in the thermoregulatory vascular beds (reviewed in Ref. 10 ). These episodes may occur apparently spontaneously or they may be evoked by experimentally controlled alerting stimuli. The episodes are referred to as "sympathetic cutaneous vasoconstrictor alerting responses," or SCVARS. We have demonstrated that nonselective inhibition of neuronal function in the amygdala substantially inhibits the occurrence of SC-VARS (43, 72, 74) .
Both systemic and intra-amygdala application of ␣ 2 -adrenergic agonists like clonidine inhibit behavioral and physiological processes that are normally part of the animal's response to salient, stressful, or fear-inducing environmental events (18, 22, 24, 25, 41, 48, 60, 61) . In the present paper, we have tested the hypothesis that release of noradrenaline within the amygdala is important for the occurrence of SCVARS. In the first series of experiments we used acute systemic and intraamygdala administration of clonidine and idazoxan (␣ 2 -adrenergic agonist and antagonist, respectively), and tested the effect on SCVARs occurring in the tail artery of conscious freely moving rats. In the second series of experiments, also in rats, we used intra-amygdala injections of saporin coupled to antibodies against dopamine-␤-hydroxylase (saporin anti-DBH) to destroy the noradrenergic neurons innervating the amygdala, including those in the locus coeruleus (11, 56, 71) . At least 1 wk after intra-amygdala administration of the immunotoxin, we assessed the occurrence of SCVARS in conscious freely moving animals.
MATERIALS AND METHODS
Animals and surgical procedures. Experiments, approved by the Animal Welfare Ethical Committee of Flinders University, were carried out on male Sprague-Dawley rats (300 -400 g). For implantation of measuring devices, rats were anesthetized with 2% isoflurane (Veterinary Companies of Australia, Kings Park, NSW, Australia) in 100% oxygen. An ultrasonic Doppler blood flow probe (Iowa Doppler Products, Iowa City, IA) was implanted around the base of the tail artery (28, 43) . In animals in which only systemic injections of drugs were planned, subcutaneous flow probe wires were connected to a head-piece, which was then attached to the skull. In animals to be used for intra-amygdala injections of drugs, intracerebral cannulas were implanted (see below), and flow probe wires were then connected to a head piece, and the head piece was attached to the skull.
Preparation for acute injection of clonidine or idazoxan into the amygdala. The procedure is fully described in Mohammed et al. (43) . Rats were anesthetized as above and stainless-steel guide cannula (26 gauge, Plastics One, Roanake, VA) were positioned bilaterally, 1 mm dorsal to the central nucleus in the amygdaloid complex [AP Ϫ2.3 mm; ML ϩ4.8 mm; DV 7.0 mm, (51) ] and fixed to the skull. Stainless-steel stylets (33 gauge), with plastic caps, were inserted into the guide cannulas. Rats were treated postoperatively with analgesic (Caprofen, Norbrook Laboratories, Melbourne, Australia; 5 mg/kg sc) and antibiotic (Baytril, Bayer Australia, Sydney; 15 mg/kg sc). Animals recovered in the Animal House for at least 1 wk.
For intra-amygdala injections, the stylet was removed from the guide cannula and replaced with an injection cannula (Hypotube S/S 304-RW stainless-steel 33 gauge, Small Parts, Miramar, FL), with the ventral tip protruding 1 mm from the tip of the guide cannula. The proximal end of the injection cannula was already attached to plastic tubing (Polypropylene Dural Plastics & Engineering, Auburn, NSW, Australia) connected to a calibrated 5-l glass micropipette (Clay Adams, Division of Becton-Dickinson, Parsippany, NJ). Either drug or vehicle was pressure injected. Movement of a fluid-air meniscus in the micropipette was used to monitor the volume of the injection.
Drugs. Clonidine hydrochloride and idazoxan hydrochloride (Sigma Chemical, St. Louis, MO) were dissolved in the Ringer solution. For systemic administration, clonidine (10 -100 g/kg) and idazoxan (1 mg/kg) were dissolved in 0.5 ml of Ringer. For intraamygdala administration, we used clonidine (10 -100 nmol in 200 nl Ringer) or idazoxan (75 nmol in 200 nl Ringer) injected bilaterally over a period of ϳ1 min. The injection cannula was removed after an additional 1 min and replaced by the stylet. The doses of clonidine and idazoxan were obtained from the literature (21, 48, 60, 61) and from our pilot experiments. We performed a dose-response pilot study of the effects of intraperitoneal idazoxan (0.1, 1, and 10 mg/kg) on the SCVAR index. There was a significant log-dose regression (P Ͻ 0.001, R 2 ϭ 0.73). The values of the SCVAR index for the increasing dose were 80 Ϯ 3%, 65 Ϯ 9%, and 12 Ϯ 6%, respectively. We chose the 1 mg/kg ip dose for our study (see DISCUSSION) .
Experimental protocol for intraperitoneal and intra-amygdala injection of drugs. On the day of the experiment, the rat was transferred to a wooden box (40 ϫ 40 ϫ 40 cm, temperature 24 -26°C) with a swivel device that could be connected by a flexible cable to the head socket. The tail artery Doppler blood flow signal was continually recorded for 20 min (see below) with the animal left undisturbed.
In an intraperitoneal dose-response study, clonidine (10, 50, or 100 g/kg) was injected intraperitoneally, and after 20 min, the alerting stimuli were administered, and the SCVAR index was as- sessed. In separate experiments, idazoxan (1 mg/kg) was injected intraperitoneally, followed after 20 min by clonidine 100 g/kg ip. After an additional 20 min, the alerting stimuli were administered, and the SCVAR index was assessed. In further separate experiments, idazoxan (75 nmol) was injected bilaterally into the amygdala, followed after 20 min by clonidine 100 g/kg ip. After an additional 20 min, the alerting stimuli were administered, and the SCVAR index was assessed.
For the bilateral intra-amygdala administration of drug studies, we established the effect of bilateral injection of vehicle (200 nl) and, in separate experiments, bilateral administration of idazoxan (75 nmol in 200 nl), with the alerting stimuli administered 20 min after the injections. An intra-amygdala dose-response study of clonidine (5, 10, and 20 nmol in 200 nl bilaterally) was performed, with the alerting stimuli administered 20 min after administration of clonidine.
In separate experiments, vehicle was injected into the amygdala bilaterally, followed after 20 min by bilateral intra-amygdala clonidine (20 nmol in 200 nl). After an additional 20 min, the alerting stimuli were administered, and the SCVAR index was assessed. In further separate experiments, idazoxan (75 nmol) was injected bilaterally into the amygdala, followed after 20 min by bilateral intraamygdala clonidine (20 nmol in 200 nl). After an additional 20 min, the alerting stimuli were administered, and the SCVAR index was assessed.
At the conclusion of each experiment, the animal was then returned to the animal house. Each rat received no more than three intraperitoneal or bilateral amygdala injections in counterbalanced order, with at least 2 days between injections. Intracerebral injection sites were marked by including fluorescent beads (FluoSpheres, Molecular Probes, Eugene, OR) or a crystal of horseradish peroxidase (Sigma V1) in the injectate of the final bilateral injection for each rat.
Preparation of rats with chronic immunotoxin lesions of the noradrenergic neurons innervating the amygdala. Rats were anesthetized and placed in the stereotaxic apparatus. Unilateral or bilateral burr holes were made in the skull. A small cut was made in the dura mater. A long-shanked 5-l glass micropipette (Accu-Fill 90; Micropet, Clay Adams, NJ), calibrated in 100-nl steps, was filled with vehicle or immunotoxin (saporin coupled to anti-DBH; Advanced Targeting, San Diego, CA). The tip of the micropipette was lowered into the amydgala (AP Ϫ2.3 mm; ML ϩ4.8 mm; DV 8.0 mm) (51) . Immunotoxin (5 g in 250 nl) or vehicle was injected during ϳ1 min, and the pipette was left in place for an additional 1 min. Further surgery for implantation of a Doppler flow probe around the base of the tail artery and a head-piece attached to the skull was then performed, as described above. Animals were returned to the animal house. Experiments were performed between 1 and 3 wk after injection of immunotoxin. Rats were transferred to the wooden box in the experimental room (see above). The tail artery Doppler blood flow signal was continually recorded for 1 h with the animal left undisturbed, and then the standardized alerting stimuli (see below) were administered.
Alerting stimuli. All experiments were conducted during the rat's 12-h dark phase. Standardized alerting stimuli were administered at least 5 min apart, at times when the tail artery blood flow was at a high level. A flexible metal rod was released from a restraint, so that it suddenly tapped the side of the wooden box. A 0.5-s, 90-dB, 100-Hz sound was made outside the box. The box was dropped 1.5 cm. The box was vigorously moved to and fro 2 or 3 times. A small window (15 ϫ 15 cm) in the front of the box was suddenly opened. The door of the box was opened and a single pinprick over the thigh was administered using a 23 G sterile needle.
Data recording and statistical analysis. The tail artery Doppler signal was transmitted via the subcutaneous wires to the head piece and then, via a flexible cable and a swivel device to a System 6 model 200 signal processor (Triton Technology, San Diego, CA). The output voltage signal was calibrated in cm/s using the Triton internal calibrator. The signal was transferred to a MacLab/s device and analyzed using Chart 7 (ADinstruments, Castle Hill, NSW, Australia), IgorPro software (Wavemetrics, Lake Oswego, Tigard, OR) and StatView (SAS Institute, Carey, NC).
We (10, 50 , and 100 g/kg) and clonidine 100 g/kg ip after pretreatment with intraperitoneal idazoxan (1 mg/kg) or bilateral intra-amygdala idazoxan (75 nmol in 200 nl). n ϭ 6 rats in each experimental condition. **Significant linear regression between log dose of clonidine and percentage coefficient of variation, P Ͻ 0.0001, R 2 ϭ 0.62. ••Significant linear regression between log dose of clonidine and SCVAR index, P Ͻ 0.0001, R 2 ϭ 0.80. ns not significantly different from pCV after injection of clonidine 100 g/kg ip without prior pretreatment, P ϭ 0.2124 for intraperitoneal idazoxan and P ϭ 0.3726 for intra-amygdala idazoxan. ¶ ¶Signifi-cantly greater than SCVAR index after injection of clonidine 100 g/kg ip, P Ͻ 0.0001 for intraperitoneal idazoxan and P Ͻ 0.0001 for intra-amygdala idazoxan. † †Significantly less than SCVAR index after intraperitoneal injection of clonidine 10 g/kg without pretreatment, P ϭ 0.0002 for intraperitoneal idazoxan and P ϭ 0.0037 for intra-amygdala idazoxan.
the standardized alerting stimuli. The SCVAR index formula was 100 Ϫ [(prestimulus mean flow ϩ prestimulus mean pulse amplitude)/ (poststimulus mean flow ϩ poststimulus mean pulse amplitude)·100]. The prestimulus flow and pulse amplitude (3-s sample) and poststimulus flow and pulse amplitude (3-s sample at lowest flow level in the 10 s after the stimulus onset) were used. The SCVAR index for each of the six alerting stimuli were averaged to obtain a single SCVAR index for each rat in each experimental condition.
Group data are shown as means Ϯ SE unless otherwise indicated. SCVAR and pCV values for each condition were analyzed using factorial ANOVA. If the overall analysis was significant at P Ͻ 0.05, groups were compared using Fisher's protected least significance difference test. In addition, for both intraperitoneal and intraamygdala experiments, we used linear regression to determine the relation between log dose of clonidine and both pCV and SCVAR index.
Histological examination of clonidine-idazoxan intracerebral injection sites, and examination of brain after injection of immunotoxin into the amygdala. After completion of experiments, rats were anesthetized with pentobarbital (100 mg/kg ip). Brains were perfused transcardially with 4% formaldehyde fixative in 0.5 M phosphate buffer, removed from the buffer, and left in the fixative overnight with 30% sucrose. Serial coronal sections (50 m) were cut using a freezing microtome.
After intracerebral injections of clonidine or idazoxan, forebrain sections processed for HRP reaction product were visualized with the diaminobenzidine (Sigma) hydrogen-peroxide reaction and counterstained for Nissl substance using Neutral Red. The fluorescent beads were examined in an Olympus AX50 fluorescence microscope.
After intra-amygdala administration of immunotoxin, animals were maintained for up to 1 mo before anesthetization and fixation of the brain, as described above. In these animals, 50-m coronal sections were cut through the forebrain and the hindbrain. Free-floating brain sections were processed immunohistochemically using a monoclonal anti-DBH raised in mouse (Millipore-Chemicon, Temecula, CA) 1/5,000, biotinylated anti-mouse (1/200) raised in goat (Sigma-Aldrich, Castle Hill, NSW, Australia) using the avidin-biotin-peroxidase procedure. Sections were examined in an Olympus BH-2 microscope using either dark-field or light-field illumination.
RESULTS
Systemic administration of clonidine. Before injection of clonidine, the tail artery blood flow record displayed rapid fluctuations between peak levels and near-zero levels (Fig. 1) . After intraperitoneal administration of clonidine, both the variability of tail artery blood flow and the acute reductions in flow elicited by alerting stimuli were substantially reduced, as can be seen in the records of individual experiments shown in Fig.  1 . After the higher dose of clonidine, these fluctuations were much less evident, and the acute reductions in flow normally elicited by alerting stimuli were substantially decreased or entirely prevented, as shown for an individual animal in Fig.  1B . Confirmation of the dose-responsive nature of these changes is provided in the group data presented in Fig. 2 , and the substantial reduction in the SCVAR index is reflected in the R 2 value (0.80) of the log dose-response regression The pCV was reduced from 80 Ϯ 9% to 38 Ϯ 2%, and the combined SCVAR index is reduced from 83 Ϯ 4% to 7 Ϯ 2%, with significance values and confirmation of dose-responsiveness documented in the legend to Fig. 2 .
After pretreatment with idazoxan (1 mg/kg ip or 75 nmol bilaterally into the amygdala) and subsequent injection of clonidine (100 g/kg ip), the SCVAR index was substantially increased compared with the value observed for clonidine 100 g/kg ip without idazoxan pretreatment (Fig. 2) . The idazoxan pretreatment (intraperitoneal and intra-amygdala) did not entirely restore the SCVAR index to the baseline (clonidine 10 g/kg ip) level (Fig. 2) . The pCVs after injection of clonidine 100 g/kg ip were not significantly increased by pretreatment with either intraperitoneal or intra-amygdala administration of idazoxan (Fig. 2) .
Bilateral injection of clonidine into the amygdala or into the striatum dorsal to the amygdala. After bilateral injection of vehicle into the amygdala, the tail artery blood flow record displayed the normal rapid fluctuations between peak levels and near-zero levels. Records of individual rats are shown in Fig. 3 , and group results are presented in Fig. 4 . After injection of vehicle, the pCV was 81 Ϯ 7%, and the SCVAR index was 80 Ϯ 4%. After bilateral intrastriatal (2 mm dorsal to the amygdala) injection of 20 nmol clonidine, the pCV was 79 Ϯ 7%, and the SCVAR index was 95 Ϯ 2%. After bilateral injection of idazoxan (75 nmol) into the amygdala, without subsequent injection of clonidine, the pCV was 49 Ϯ 4% and the SCVAR index was 82 Ϯ 3% (see Fig. 3B for an individual record).
After bilateral intra-amygdala injection of clonidine (5, 10, and 20 nmol) there was a dose-dependent reduction in both the pCV and the SCVAR index. The pCV was decreased from 80 Ϯ 9% to 38 Ϯ 2%, and the combined SCVAR index was decreased from 83 Ϯ 4% to 7 Ϯ 2%, with significance values documented in the legend to Fig. 2 .
After pretreatment with vehicle bilaterally into the amygdala and subsequent injection of clonidine (20 nmol) bilaterally into the amygdala, neither the pCV nor the SCVAR index was changed from the corresponding clonidine 20 nmol intraamygdala values obtained with no vehicle pretreatment (see Fig. 4 and caption to Fig. 4 for statistical documentation) . After pretreatment with idazoxan (75 nmol) bilaterally into the amygdala and subsequent injection of clonidine (20 nmol) bilaterally into the amygdala, the SCVAR index was substantially increased compared with the corresponding value after bilateral intra-amygdala injection of vehicle followed by bilateral intra-amygdala injection of clonidine (20 nmol), although the SCVAR index value (65 Ϯ 4%) was still less than the value (81 Ϯ 7%) recorded after bilateral injection of vehicle into the amygdala without any other treatment, as documented in Fig. 4 .
Bilateral injection of anti-DBH saporin immunotoxin into the amygdala.
After unilateral or bilateral intra-amygdala injections of immunotoxin, the pCV and the SCVAR index were substantially reduced compared with the corresponding values obtained at least 1 wk after similar injection of vehicle. Indi- ••Significant linear regression between log dose of clonidine and SCVAR index, P Ͻ 0.0001, R 2 ϭ 0.77. ns, not significantly different from pCV after injection of clonidine 20 nmol into amygdala following bilateral injection of vehicle into the amygdala, P ϭ 0.068. ¶ ¶Significantly greater than SCVAR index after injection of clonidine 20 nmol into amygdala following bilateral injection of vehicle into the amygdala, P Ͻ 0.0001. † †Sig-nificantly less than SCVAR index after bilateral injection of vehicle into amygdala, P ϭ 0.0058. vidual records are presented in Fig. 5 , and group results are presented in Fig. 6 . Bilateral administration of immunotoxin caused a greater reduction in the SCVAR index compared with unilateral administration (Fig. 6) .
Histological findings. Figure 7 is a representative coronal section at the level of the amygdala complex of nuclei, stained with the DAB reaction after HRP was included in the clonidine-containing cannula directed at the amygdala. The reaction product is present in the amygdala subnuclei, which spread to portions of the surrounding temporal lobe.
Immunohistochemical staining with antibodies to DBH after unilateral intra-amygdala injections of immunotoxin documented virtually complete destruction of noradrenergic axonal processes in virtually the whole of the ipsilateral telencephalon, including the amygdaloid complex of nuclei and the surrounding temporal lobe (Fig. 8, A and C) . In contrast, after unilateral injection of vehicle, there were normal DBH-positive axonal processes in these regions (Fig. 8, B and D) . After unilateral intra-amygdala injection of immunotoxin, the rostral two-thirds of the ipsilateral locus coeruleus was substantially destroyed, with preservation of the contralateral locus coeruleus (Fig. 8, E and F) . After bilateral intra-amygdala injections of immunotoxin, neurons in the rostral two-thirds of both locus coerulei were destroyed, but the ventrolaterally situated A7 neuronal perikarya were intact, as were the A5 neurons (not shown). The A1 and A2 noradrenergic neurons in the caudal medulla were also affected after intra-amygdala injections of immunotoxin, but the degree of loss was difficult to quantify.
DISCUSSION
After either systemic or intra-amygdala administration, clonidine reduced both spontaneous reductions in tail artery blood flow and those induced by alerting stimuli controlled by the experimenter. The clonidine-elicited reductions were dosedependent for both routes of administration. The R 2 value for the regression between intra-amygdala log dose of clonidine and SCVAR index was 0.77, and the R 2 value for the regression between IP log dose of clonidine and SCVAR index was 0.80, indicating a substantial SCVAR-inhibiting effect after both routes of administration. The effect of clonidine on the falls in tail blood flow normally observed to the controlled administration of alerting stimuli was especially substantial, so that the percentage decrease in flow (the SCVAR index) was reduced from ϳ80% to ϳ7% after intraperitoneal injections and to ϳ15% after intra-amygdala injections. When the maximum dose of clonidine was injected into the striatum dorsal to the amygdala, there was no reduction in the SCVAR index.
Pretreatment with the ␣ 2 -adrenergic antagonist idazoxan, administered systemically or via direct injection into the amygdala, significantly prevented the SCVAR inhibitory effects of systemic clonidine, and pretreatment with intraamygdala idazoxan substantially prevented the inhibitory effects of subsequent intra-amygdala clonidine. The intraperitoneal dose of idazoxan used in our experiments (1 mg/kg) is at the upper end of the range used by other investigators (e.g., 21) , and this dose of the drug, administered by itself, did reduce the SCVAR index. However, the intra-amygdala dose of idazoxan (75 nmol), by itself, had no effect on the SCVAR index, but it substantially prevented the inhibitory effect of subsequently administered clonidine (both intraperitoneal and intra-amygdala). We appreciate that idazoxan also interacts with imidazole receptors (31) . However, taken together, the idazoxan results in our experiments strongly support the view that the SCVAR-inhibitory action of clonidine is mediated by actions at ␣ 2 -adrenergic receptors, including receptors in the amygdala.
Clonidine, via its agonist action at ␣ 2 -adrenergic receptors, inhibits the release of noradrenaline from noradrenergic nerve terminals (26, 50, 63, 64, 68) . Clonidine, administered systemically or into specific brain regions, also hyperpolarizes and decreases the discharge of noradrenergic perikarya, as first demonstrated in Aghajanian's laboratory (1, 17, 65) . Thus, in the present experiments, systemically administered clonidine might also inhibit amygdala neurons by decreasing the discharge of locus coeruleus neurons, thereby reducing noradrenergic excitation of amygdala neurons mediated via ␣ 1 -adrenergic or ␤-adrenergic receptors. Our saporin anti-DBH experiments support this view. The retrogradely transported immunotoxin substantially destroyed the rostral two-thirds of the locus coeruleus, virtually eliminating the noradrenergic innervation of the amygdala, as well as the remainder of the U Un ni il la at te er ra al l i im mm mu un no ot to ox xi in n U Un ni il la at te er ra al l v ve eh hi ic cl le e U Un ni il la at te er ra al l v ve eh hi ic cl le e U Un ni il la at te er ra al l i im mm mu un no ot to ox xi in n C Ca an nn nu ul la a t tr ra ac ct t
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Un ni il la at te er ra al l i im mm mu un no ot to ox xi in n subC c co on nt tr ra al la at te er ra al l i ip ps si il la at te er ra al l i ip ps si il la at te er ra al l telencephalon. After unilateral intra-amygdala injections of immunotoxin, neuronal destruction was observed principally in LC, consistent with the known principally unilateral projection of locus coeruleus axons to the telencephalon (29, 42, 46, 49) . We also observed damage to the A1 and A2 groups of neurons in the medulla oblongata that also provide noradrenergic input to the amygdala (49, 54) , but quantification of this damage was difficult. Clonidine, after both systemic and intra-amygdala administration in doses generally similar to those used in the present study, has been shown to inhibit a number of behavioral and physiological processes that are normally part of the animal's response to salient, stressful, or fear-inducing environmental events (14, 18, 20, 22, 24, 25, 47, 48, 52, 60, 61) . We have demonstrated in both rabbits and rats that acute vasoconstriction in thermoregulatory beds elicited by alerting stimuli is immediately preceded by a sudden increase in the proportion of rhythm in the hippocampal EEG (19, 73) , a reliable indication that the animal is suddenly directing attention to a possible threat in the external environment (15, 16) . Thus, our present study adds to the evidence that the noradrenergic innervation of the amygdala, deriving principally from the locus coeruleus, contributes to the autonomic responses associated with the processing of salient, and possibly threatening, environmental stimuli.
Madden et al. (41) demonstrated that administration of clonidine systemically and directly into the rostral raphe pallidus region inhibits brown adipose tissue (BAT) thermogenesis and lowers body temperature. The authors propose that clonidine acts on postsynaptic ␣ 2 -receptors located on bulbospinal neurons known to regulate the sympathetic outflow to BAT (30) . Bulbospinal neurons in the rostral raphe pallidus, including serotonin-synthesizing neurons, also control the sympathetic outflow to the tail artery (10) , so that systemically applied clonidine could contribute to inhibition of SCVARs via actions on ␣ 2 -receptors in the rostral raphe pallidus region. Presynaptic actions of clonidine on terminals of catecholamine-synthesizing neurons innervating the rostral raphe pallidus (see review in Ref. 41) could also contribute to these actions. Increased body temperature via brown adipose tissue thermogenesis and cutaneous vasoconstriction is part of the autonomic response to emotional arousal (10, 44) , so that the present results complement those of Madden et al. (41) .
We appreciate that the size of our clonidine injections and the widespread destruction of noradrenergic terminals after our intra-amygdala injections of immunotoxin means that our study does not allow us to make conclusions concerning specific subnuclei within the amygdala. Nevertheless, taken together, our clonidine and immunotoxin results provide strong evidence that inhibiting the release of noradrenaline within the region of the amygdaloid complex of nuclei inhibits the central nervous system (CNS) processing of salient events and the resultant activation of the sympathetic outflow to the thermoregulatory vascular beds.
Perspectives and Significance
Pharmacological manipulation of ␣ 2 -adrenoceptors in the CNS has contributed to the therapeutic management of medical conditions related to emotional arousal, including hypertension (55) and major neuropsychiatric disorders (13, 38) . The wide range of behavioral and physiological variables affected by clonidine-like agents presumably reflects the widespread distribution and axonal projections of noradrenergic neurons in the brain. In particular, the locus coeruleus has been implicated in many aspects of emotional arousal (2) , so that functional inhibition of the extensive locus coeruleus-derived noradrenergic innervation of centers know to be important in emotional arousal, including the amygdala, is likely to contribute to the therapeutic actions of clonidine-like agents. The locus coeruleus also has major reciprocal connections with the orexinsynthesizing neurons in the hypothalamus (76) , and rats with genetically lesioned orexin neurons have reduced emotional arousal as reflected in reduced SCVAR responses to alerting stimuli, reduced thermogenic responses to an intruder rat, and a reduced amplitude of the increases in a number of physiological variables associated with the ultradian basic rest-activity cycle (45) . Clonidine has similar effects on these physiological variables (39, 41) , so that it may well be that the noradrenergic input to the orexin neurons is also inhibited by clonidine. Clozapine and clozapine-like drugs, antipsychotic agents that powerfully reduce the behavioral and physiological aspects of emotional arousal, interact with ␣ 2 -adrenergic receptors (13) , so that the neural mechanisms, whereby clonidine reduces emotional arousal may overlap with those mediating the therapeutic effects of clozapine-like antipsychotic agents.
